Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Moldt

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
AIDS (London, England)|June 1, 2016
Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaquesBrian Moldt, Khoa M Le, Diane G Carnathan, et al.
Plos Pathogens|November 27, 2013
The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cellsSandeep Gupta, Johannes S Gach, Juan C Becerra, et al.
Science Translational Medicine|January 4, 2013
Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutantRozh H Al-Mashhadi, Charlotte B Sørensen, Peter M Kragh, et al.
Science Translational Medicine|June 24, 2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapyDevi SenGupta, Cynthia Brinson, Edwin DeJesus, et al.
AIDS (London, England)|September 29, 2021
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individualsBrian Moldt, Huldrych F Günthard, Kimberly A Workowski, et al.
The Journal of Experimental Medicine|August 27, 2014
Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaquesMasashi Shingai, Olivia K Donau, Ronald J Plishka, et al.
Cell Host & Microbe|September 12, 2014
Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteinsGregory Q Del Prete, Braiden Eilers, Brian Moldt, et al.
Journal of Virology|March 30, 2012
A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaquesBrian Moldt, Mami Shibata-Koyama, Eva G Rakasz, et al.
Nature|November 1, 2013
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeysDan H Barouch, James B Whitney, Brian Moldt, et al.
Science (New York, N.Y.)|June 20, 2015
HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimersRogier W Sanders, Marit J van Gils, Ronald Derking, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
AIDS (London, England)|June 1, 2016
Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaquesBrian Moldt, Khoa M Le, Diane G Carnathan, et al.
Plos Pathogens|November 27, 2013
The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cellsSandeep Gupta, Johannes S Gach, Juan C Becerra, et al.
Science Translational Medicine|January 4, 2013
Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutantRozh H Al-Mashhadi, Charlotte B Sørensen, Peter M Kragh, et al.
Science Translational Medicine|June 24, 2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapyDevi SenGupta, Cynthia Brinson, Edwin DeJesus, et al.
AIDS (London, England)|September 29, 2021
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individualsBrian Moldt, Huldrych F Günthard, Kimberly A Workowski, et al.
The Journal of Experimental Medicine|August 27, 2014
Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaquesMasashi Shingai, Olivia K Donau, Ronald J Plishka, et al.
Cell Host & Microbe|September 12, 2014
Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteinsGregory Q Del Prete, Braiden Eilers, Brian Moldt, et al.
Journal of Virology|March 30, 2012
A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaquesBrian Moldt, Mami Shibata-Koyama, Eva G Rakasz, et al.
Nature|November 1, 2013
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeysDan H Barouch, James B Whitney, Brian Moldt, et al.
Science (New York, N.Y.)|June 20, 2015
HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimersRogier W Sanders, Marit J van Gils, Ronald Derking, et al.
Pageof 4